BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| BMRN | BIOMARIN PHARMACEUTICAL INC | 2026-03-03 13:34:39 | 59.18 | -0.56 | -0.94 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMRN | 0001048477 | BIOMARIN PHARMACEUTICAL INC | US09061G1013 | NSLL8ITTRR0J5HEMR848 | 680397820 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 105 DIGITAL DRIVE | NOVATO | CA | 94949 | UNITED STATES | US | 4155066700 | 105 DIGITAL DRIVE, NOVATO, CA, 94949 | 105 DIGITAL DRIVE, NOVATO, CA, 94949 | — | Biotechnology | 1997 | Alexander Hardy | 3,401 | http://biomarin.com | 8,700,000,000 | 192,098,751 | 192,114,344 | BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU). | 2026-02-26 16:03:13 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 6,700,000,000 | -2,000,000,000 | -22.9885 | 192,323,359 | 1,546,307 | 0.8105 |
| 2024 | 8,700,000,000 | -1,400,000,000 | -13.8614 | 190,777,052 | 2,101,430 | 1.1138 |
| 2023 | 10,100,000,000 | 1,100,000,000 | 12.2222 | 188,675,622 | 2,146,838 | 1.1509 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| G. Eric Davis | Chief Legal Officer, Executive Vice President | 2024 | 722,115 | 0 | 2,880,871 | 565,500 | 22,996 | 5,058,665 |
| Gregory R. Friberg, M.D. | Executive Vice President | 2024 | 161,538 | 250,000 | 5,092,722 | 123,068 | 102,719 | 7,221,559 |
| Alexander Hardy | CEO, President | 2024 | 1,050,000 | 0 | 10,490,968 | 1,501,500 | 149,571 | 14,853,605 |
| Brian R. Mueller | Executive Vice President, CFO | 2024 | 699,231 | 0 | 3,199,820 | 613,350 | 22,798 | 5,498,568 |
| Cristin Hubbard | Chief Commercial Officer, Executive Vice President | 2024 | 382,846 | 600,000 | 4,030,774 | 491,400 | 292,947 | 6,928,261 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 3,221 |
| 2024 | 3,040 |
| 2023 | 3,401 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 3,221,253,000 | 2,853,915,000 | 2,419,226,000 |
| Cost Of Revenue | 717,442,000 | 580,235,000 | 514,854,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 921,930,000 | 747,184,000 | 746,773,000 |
| General And Administrative Expenses | 1,153,017,000 | 1,009,025,000 | 937,291,000 |
| Operating Expenses | 2,811,775,000 | 2,369,701,000 | 2,261,129,000 |
| Operating Income | 409,478,000 | 484,214,000 | 158,097,000 |
| Net Income | 348,901,000 | 426,859,000 | 167,645,000 |
| Earnings Per Share Basic | 1.82 | 2.25 | 0.89 |
| Earnings Per Share Diluted | 1.8 | 2.21 | 0.87 |
| Weighted Average Shares Outstanding Basic | 191,787,000 | 190,027,000 | 187,834,000 |
| Weighted Average Shares Outstanding Diluted | 197,394,000 | 196,708,000 | 191,595,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 1,311,679,000 | 942,842,000 | 755,127,000 |
| Marketable Securities Current | 248,930,000 | 194,864,000 | 318,683,000 |
| Accounts Receivable | 908,214,000 | 660,535,000 | 633,704,000 |
| Inventories | 1,298,883,000 | 1,232,653,000 | 1,107,183,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 185,784,000 | 201,533,000 | 141,391,000 |
| Total Assets Current | 3,953,490,000 | 3,232,427,000 | 2,956,088,000 |
| Marketable Securities Non Current | 492,242,000 | 521,238,000 | 611,135,000 |
| Property Plant And Equipment | 952,508,000 | 1,043,041,000 | 1,066,133,000 |
| Other Assets Non Current | 277,049,000 | 251,391,000 | 171,538,000 |
| Total Assets Non Current | 991,797,000 | 1,076,792,000 | 1,112,207,000 |
| Total Assets | 7,594,022,000 | 6,988,940,000 | 6,841,603,000 |
| Accounts Payable | 759,031,000 | 606,988,000 | 683,147,000 |
| Deferred Revenue | — | 1,369,000 | 4,620,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 3,667,000 | 12,567,000 | 2,651,000 |
| Total Liabilities Current | 759,031,000 | 606,988,000 | 1,177,024,000 |
| Long Term Debt | 597,176,000 | 595,138,000 | 593,095,000 |
| Other Liabilities Non Current | 150,816,000 | 128,824,000 | 119,935,000 |
| Total Liabilities Non Current | 747,992,000 | 723,962,000 | 713,030,000 |
| Total Liabilities | 1,507,023,000 | 1,330,950,000 | 1,890,054,000 |
| Common Stock | 192,000 | 191,000 | 189,000 |
| Retained Earnings | 154,206,000 | -194,695,000 | -621,554,000 |
| Accumulated Other Comprehensive Income | -13,473,000 | 61,653,000 | -28,788,000 |
| Total Shareholders Equity | 6,086,999,000 | 5,657,990,000 | 4,951,549,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 79,557,000 | 96,426,000 | 104,386,000 |
| Share Based Compensation Expense | 181,409,000 | 201,571,000 | 207,099,000 |
| Other Non Cash Income Expense | 4,414,000 | -20,135,000 | 365,000 |
| Change In Accounts Receivable | 228,054,000 | 57,909,000 | 190,435,000 |
| Change In Inventories | 116,929,000 | 63,530,000 | 157,058,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 66,136,000 | -32,240,000 | 68,853,000 |
| Change In Other Liabilities | 14,869,000 | 14,761,000 | 23,585,000 |
| Cash From Operating Activities | 827,994,000 | 572,841,000 | 159,259,000 |
| Purchases Of Marketable Securities | 355,875,000 | 410,250,000 | 868,496,000 |
| Sales Of Marketable Securities | 337,801,000 | 633,018,000 | 864,863,000 |
| Acquisition Of Property Plant And Equipment | 103,038,000 | 85,424,000 | 96,691,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | 0 | -1,141,000 | 0 |
| Cash From Investing Activities | -414,242,000 | 136,491,000 | -111,244,000 |
| Tax Withholding For Share Based Compensation | 55,965,000 | 77,560,000 | 76,319,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | -889,000 | -3,177,000 | 0 |
| Cash From Financing Activities | -42,394,000 | -526,447,000 | -18,727,000 |
| Change In Cash | 368,837,000 | 187,715,000 | 30,596,000 |
| Cash At End Of Period | 1,311,679,000 | 942,842,000 | 755,127,000 |
| Income Taxes Paid | 96,205,000 | 57,269,000 | 73,312,000 |
| Interest Paid | 7,245,000 | 10,361,000 | 10,303,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 1.82 | 2.25 | 0.89 |
| Price To Earnings Ratio | 32.6538 | 29.2133 | 108.3371 |
| Earnings Growth Rate | -19.1111 | 152.809 | 17.1053 |
| Price Earnings To Growth Ratio | -1.7086 | 0.1912 | 6.3336 |
| Book Value Per Share | 31.7383 | 29.7747 | 26.3613 |
| Price To Book Ratio | 1.8725 | 2.2076 | 3.6576 |
| Ebitda | 535,562,000 | 593,220,000 | 362,678,000 |
| Enterprise Value | 10,683,398,410 | 12,142,770,710 | 17,948,922,280 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.0981 | 0.1052 | 0.1198 |
| Capital Expenditures | -10,976,000 | 73,334,000 | 97,153,000 |
| Free Cash Flow | 838,970,000 | 499,507,000 | 62,106,000 |
| Return On Equity | 0.0573 | 0.0754 | 0.0339 |
| One Year Beta | 0.732 | 0.6739 | 0.6897 |
| Three Year Beta | 0.7039 | 0.7163 | 0.7494 |
| Five Year Beta | 0.7332 | 0.8012 | 0.8375 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Davis George Eric | EVP, Chief Legal Officer | 2026-02-26 | 26,061 | D | 72,453 |
| Friberg Gregory R | EVP, Chief R&D Officer | 2026-02-26 | 6,326 | D | 37,578 |
| Mueller Brian | EVP, Chief Financial Officer | 2026-02-25 | 6,683 | A | 106,839 |
| Mueller Brian | EVP, Chief Financial Officer | 2026-02-25 | 7,230 | A | 114,069 |
| Mueller Brian | EVP, Chief Financial Officer | 2026-02-25 | 2,569 | A | 116,638 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Daniel Goldman | 2023-04-17 | NY10 | Sale | 2023-03-06 | — | $1,001 - $15,000 |
| Josh Gottheimer | 2020-01-06 | NJ05 | Purchase | 2019-12-11 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2020-01-06 | NJ05 | Purchase | 2019-12-16 | Joint | $1,001 - $15,000 |
| Alan S. Lowenthal | 2019-09-01 | CA47 | Sale | 2019-08-15 | Spouse | $1,001 - $15,000 |
| Alan S. Lowenthal | 2019-09-01 | CA47 | Sale (Partial) | 2019-08-14 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| NOVO HOLDINGS A/S | 2025-12-31 | 39,223,800 | 660,000 | 59.43 |
| Palo Alto Investors LP | 2025-12-31 | 44,349,994 | 746,256 | 59.43 |
| Jain Global LLC | 2025-12-31 | 1,156,032 | 19,452 | 59.43 |
| Investment Management Corp of Ontario | 2025-12-31 | 418,744 | 7,046 | 59.43 |
| TUDOR INVESTMENT CORP ET AL | 2025-12-31 | 1,586,781 | 26,700 | 59.43 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| DODGE & COX FUNDS | 2025-12-31 | Class I | DODGX | 9,769,625 | 580,608,813.75 | 0.4848 |
| Victory Portfolios II | 2025-12-31 | VictoryShares Small Cap Free Cash Flow ETF | SFLO | 75,597 | 4,492,729.71 | 1.0092 |
| VanEck ETF Trust | 2025-12-31 | VanEck Morningstar SMID Moat ETF | SMOT | 44,806 | 2,662,820.58 | 0.7447 |
| VanEck ETF Trust | 2025-12-31 | VanEck Biotech ETF | BBH | 77,097 | 4,581,874.71 | 1.2192 |
| HC CAPITAL TRUST | 2025-12-31 | The Institutional U.S. Equity Portfolio | HCIGX | 15,374 | 913,676.82 | 0.0305 |